{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:09:04Z","timestamp":1781719744281,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR Cambridge Biomedical Research Center","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}]},{"name":"NIHR Cambridge Biomedical Research Center","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}]},{"name":"NIHR Cambridge Biomedical Research Center","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}]},{"name":"NIHR Cambridge Biomedical Research Center","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the potential for <jats:sup>11<\/jats:sup>C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET\/MR<jats:sup>CR<\/jats:sup>) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>Thirteen patients with pituitary microprolactinomas, and who were intolerant (<jats:italic>n\u2009<\/jats:italic>=\u200911) or resistant (<jats:italic>n\u2009<\/jats:italic>=\u20092) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET\/MR<jats:sup>CR<\/jats:sup> between 2016 and 2020. All patients had persistent hyperprolactinemia and were being considered for surgical intervention, but standard clinical MRI had shown either no visible adenoma or equivocal appearances.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In all 13 patients Met-PET\/MR<jats:sup>CR<\/jats:sup> demonstrated a single focus of avid tracer uptake. This was localized either to the right or left side of the sella in 12 subjects. In one patient, who had previously undergone surgery for a left-sided adenoma, recurrent tumor was unexpectedly identified in the left cavernous sinus. Five patients underwent endoscopic transsphenoidal selective adenomectomy, with subsequent complete remission of hyperprolactinaemia and normalization of other pituitary function; three patients are awaiting surgery. In the patient with inoperable cavernous sinus disease PET-guided stereotactic radiosurgery (SRS) was performed with subsequent near-normalization of serum prolactin. Two patients elected for a further trial of medical therapy, while two declined surgery or radiotherapy and chose to remain off medical treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with dopamine agonist intolerance or resistance, and indeterminate pituitary MRI, molecular (functional) imaging with Met-PET\/MR<jats:sup>CR<\/jats:sup> can allow precise localization of a microprolactinoma to facilitate selective surgical adenomectomy or SRS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-022-01229-9","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T06:04:56Z","timestamp":1653372296000},"page":"573-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"W. A.","family":"Bashari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Senanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Powlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Scoffings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tysome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Santarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Boros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Aigbirhio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. K.","family":"Cheow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Mendichovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Kolias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mannion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Koulouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gurnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ando.2012.03.039","volume":"73","author":"N Karavitaki","year":"2012","unstructured":"Karavitaki N (2012) Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris) 73:79\u201380. https:\/\/doi.org\/10.1016\/j.ando.2012.03.039","journal-title":"Ann Endocrinol (Paris)"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","volume":"44","author":"A Glezer","year":"2015","unstructured":"Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin North Am 44:71\u201378. https:\/\/doi.org\/10.1016\/j.ecl.2014.11.003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7599\/hmr.2012.32.4.192","volume":"68","author":"M Kars","year":"2010","unstructured":"Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104\u2013112. https:\/\/doi.org\/10.7599\/hmr.2012.32.4.192","journal-title":"Neth J Med"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18:752\u2013776. https:\/\/doi.org\/10.1007\/s11102-015-0636-7","journal-title":"Pituitary"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejm199410063311403","volume":"8","author":"J Webster","year":"1995","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1995) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. ACOG Curr J Rev 8:24. https:\/\/doi.org\/10.1056\/nejm199410063311403","journal-title":"ACOG Curr J Rev"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/nejmoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338. https:\/\/doi.org\/10.1056\/nejmoa062222","journal-title":"N Engl J Med"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/jc.2018-01071","volume":"104","author":"CE Stiles","year":"2018","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick JP, Steeds RP, Drake WM (2018) A meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline. J Clin Endocrinol Metab 104:523\u2013538. https:\/\/doi.org\/10.1210\/jc.2018-01071","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ncpendmet0160","volume":"2","author":"A Colao","year":"2006","unstructured":"Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G (2006) Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2:200\u2013210. https:\/\/doi.org\/10.1038\/ncpendmet0160","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W (2019) Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf) 90:662\u2013669. https:\/\/doi.org\/10.1111\/cen.13940","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J et al (2020) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab 105:e108\u2013e118. https:\/\/doi.org\/10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104:2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","volume":"62","author":"E Celik","year":"2018","unstructured":"Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P (2018) Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine 62:692\u2013700. https:\/\/doi.org\/10.1007\/s12020-018-1744-8","journal-title":"Endocrine"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 80:863\u2013868. https:\/\/doi.org\/10.1111\/cen.12375","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P (2011) Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol 34:179\u2013181. https:\/\/doi.org\/10.1097\/WNF.0b013e3182281b2f","journal-title":"Clin Neuropharmacol"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","volume":"51","author":"S Noronha","year":"2016","unstructured":"Noronha S, Stokes V, Karavitaki N, Grossman A (2016) Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51:205\u2013210. https:\/\/doi.org\/10.1007\/s12020-015-0727-2","journal-title":"Endocrine"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485\u2013534. https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42\u201350. https:\/\/doi.org\/10.1159\/000495775","journal-title":"Neuroendocrinology"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, De Vries F, Broersen LHA, Van Den Akker-Van Marle ME, Pereira AM et al (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab 105:e32\u2013e41. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9930059","volume":"2021","author":"J Lu","year":"2021","unstructured":"Lu J, Cai L, Wu Z, Lin W, Xu J, Zhu Z et al (2021) Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis. Int J Endocrinol 2021:1\u201311. https:\/\/doi.org\/10.1155\/2021\/9930059","journal-title":"Int J Endocrinol"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11102-021-01168-x","volume":"24","author":"JY Park","year":"2021","unstructured":"Park JY, Choi W, Hong AR, Yoon JH, Kim HK, Jang W-Y et al (2021) Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary 24:955\u2013963. https:\/\/doi.org\/10.1007\/s11102-021-01168-x","journal-title":"Pituitary"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/JCMA.0000000000000584","volume":"84","author":"TY Chen","year":"2021","unstructured":"Chen TY, Lee CH, Yang MY, Shen CC, Yang YP, Chien Y et al (2021) Treatment of hyperprolactinemia: a single-institute experience. J Chinese Med Assoc 84:1019\u20131022. https:\/\/doi.org\/10.1097\/JCMA.0000000000000584","journal-title":"J Chinese Med Assoc"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","volume":"24","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, Gralla J, Schubert GA et al (2021) Impact of primary medical or surgical therapy on prolactinoma patients\u2019 BMI and metabolic profile over the long-term. J Clin Transl Endocrinol 24:100258. https:\/\/doi.org\/10.1016\/j.jcte.2021.100258","journal-title":"J Clin Transl Endocrinol"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.3390\/cancers13133252","volume":"13","author":"PP Mattogno","year":"2021","unstructured":"Mattogno PP, D\u2019alessandris QG, Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A et al (2021) Reappraising the role of trans-sphenoidal surgery in prolactin-secreting pituitary tumors. Cancers (Basel) 13:3252. https:\/\/doi.org\/10.3390\/cancers13133252","journal-title":"Cancers (Basel)"},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","volume":"87","author":"PR Jethwa","year":"2016","unstructured":"Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK (2016) Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg 87:65\u201376. https:\/\/doi.org\/10.1016\/j.wneu.2015.10.090","journal-title":"World Neurosurg"},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-0036-1592193","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A et al (2017) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surgery, Part B Skull Base 78:125\u2013131. https:\/\/doi.org\/10.1055\/s-0036-1592193","journal-title":"J Neurol Surgery, Part B Skull Base"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23:45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.nec.2019.05.010","volume":"30","author":"DA Donoho","year":"2019","unstructured":"Donoho DA, Laws ER (2019) The role of surgery in the management of prolactinomas. Neurosurg Clin N Am 30:509\u2013514. https:\/\/doi.org\/10.1016\/j.nec.2019.05.010","journal-title":"Neurosurg Clin N Am"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/neuros\/nyy385","volume":"85","author":"A Micko","year":"2019","unstructured":"Micko A, Vila G, H\u00f6ftberger R, Knosp E, Wolfsberger S (2019) Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Clin Neurosurg 85:508\u2013515. https:\/\/doi.org\/10.1093\/neuros\/nyy385","journal-title":"Clin Neurosurg"},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000442327","volume":"45","author":"J-F Bonneville","year":"2016","unstructured":"Bonneville J-F (2016) Magnetic resonance imaging of pituitary tumors. Front Horm Res 45:97\u2013120. https:\/\/doi.org\/10.1159\/000442327","journal-title":"Front Horm Res"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00330-004-2531-x","volume":"15","author":"J-F Bonneville","year":"2005","unstructured":"Bonneville J-F, Bonneville F, Cattin F (2005) Magnetic resonance imaging of pituitary adenomas. Eur Radiol 15:543\u20138. https:\/\/doi.org\/10.1007\/s00330-004-2531-x","journal-title":"Eur Radiol"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-16-0639","volume":"175","author":"O Koulouri","year":"2016","unstructured":"Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS et al (2016) Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur J Endocrinol 175:485\u2013498. https:\/\/doi.org\/10.1530\/EJE-16-0639","journal-title":"Eur J Endocrinol"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"M107","DOI":"10.1530\/EJE-15-0616","volume":"173","author":"O Koulouri","year":"2015","unstructured":"Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA et al (2015) A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur J Endocrinol 173:M107\u2013M120. https:\/\/doi.org\/10.1530\/EJE-15-0616","journal-title":"Eur J Endocrinol"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2020.3.FOCUS2052","volume":"48","author":"WA Bashari","year":"2020","unstructured":"Bashari WA, Senanayake R, Koulouri O, Gillett D, MacFarlane J, Powlson AS et al (2020) PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus 48:E8. https:\/\/doi.org\/10.3171\/2020.3.FOCUS2052","journal-title":"Neurosurg Focus"},{"key":"1229_CR35","first-page":"406","volume":"369","author":"C Muhr","year":"1986","unstructured":"Muhr C, Bergstr\u00f6m M, Lundberg PO, Bergstr\u00f6m K, L\u00e5ngstr\u00f6m B (1986) In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. Acta Radiol Suppl 369:406\u2013408","journal-title":"Acta Radiol Suppl"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00004728-198603000-00001","volume":"10","author":"C Muhr","year":"1986","unstructured":"Muhr C, Bergstr\u00f6m M, Lundberg PO, Bergstr\u00f6m K, Hartvig P, Lundqvist H et al (1986) Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone. J Comput Assist Tomogr 10:175\u2013180. https:\/\/doi.org\/10.1097\/00004728-198603000-00001","journal-title":"J Comput Assist Tomogr"},{"key":"1229_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/BF00181283","volume":"18","author":"BGJ Daemen","year":"1991","unstructured":"Daemen BGJ, Zwertbroek R, Elsinga PH, Paans AJM, Doorenbos H, Vaalburg W (1991) PET studies with l-[1-11C]tyrosine, l-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur J Nucl Med 18:453\u2013460. https:\/\/doi.org\/10.1007\/BF00181283","journal-title":"Eur J Nucl Med"},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1097\/RLU.0000000000001085","volume":"41","author":"Z Feng","year":"2016","unstructured":"Feng Z, He D, Mao Z, Wang Z, Zhu Y, Zhang X et al (2016) Utility of 11C-methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas. Clin Nucl Med 41:e130\u2013e134. https:\/\/doi.org\/10.1097\/RLU.0000000000001085","journal-title":"Clin Nucl Med"},{"key":"1229_CR39","first-page":"412","volume":"369","author":"M Bergstr\u00f6m","year":"1986","unstructured":"Bergstr\u00f6m M, Muhr C, Lundberg PO, Bergstr\u00f6m K, Lundqvist H, L\u00e5ngstr\u00f6m B (1986) Amino acid metabolism in pituitary adenomas. Acta Radiol Suppl 369:412\u2013414","journal-title":"Acta Radiol Suppl"},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00004728-198709000-00014","volume":"11","author":"M Bergstrom","year":"1987","unstructured":"Bergstrom M, Muhr C, Lundberg PO, Bergstr\u00f6m K, Gee AD, Fasth KJ et al (1987) Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 11:815\u2013819. https:\/\/doi.org\/10.1097\/00004728-198709000-00014","journal-title":"J Comput Assist Tomogr"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000095529","volume":"83","author":"C Muhr","year":"2006","unstructured":"Muhr C (2006) Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology 83:205\u2013210. https:\/\/doi.org\/10.1159\/000095529","journal-title":"Neuroendocrinology"},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"57S","DOI":"10.2967\/jnumed.120.251546","volume":"62","author":"WA Bashari","year":"2021","unstructured":"Bashari WA, Senanayake R, MacFarlane J, Gillett D, Powlson AS, Kolias A et al (2021) Using molecular imaging to enhance decision making in the management of pituitary adenomas. J Nucl Med 62:57S-62S. https:\/\/doi.org\/10.2967\/jnumed.120.251546","journal-title":"J Nucl Med"},{"key":"1229_CR43","first-page":"610","volume":"32","author":"M Bergstrom","year":"1991","unstructured":"Bergstrom M, Muhr C, Lundberg PO, Langstrom B (1991) PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 32:610\u2013615","journal-title":"J Nucl Med"},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"20160098","DOI":"10.1259\/bjrcr.20160098","volume":"3","author":"N Taku","year":"2017","unstructured":"Taku N, Koulouri O, Scoffings D, Gurnell M, Burnet N (2017) The use of 11carbon methionine positron emission tomography (PET) imaging to enhance radiotherapy planning in the treatment of a giant, invasive pituitary adenoma. BJR Case Reports 3:20160098. https:\/\/doi.org\/10.1259\/bjrcr.20160098","journal-title":"BJR Case Reports"},{"key":"1229_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jlcr.1483","volume":"51","author":"V G\u00f3mez","year":"2008","unstructured":"G\u00f3mez V, Gispert JD, Amador V, Llop J (2008) New method for routine production of L-[methyl-11C]methionine: in loop synthesis. J Label Compd Radiopharm 51:83\u201386. https:\/\/doi.org\/10.1002\/jlcr.1483","journal-title":"J Label Compd Radiopharm"},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/(SICI)1099-1344(199908)42:8<715::AID-JLCR224>3.0.CO;2-3","volume":"42","author":"C Pascali","year":"1999","unstructured":"Pascali C, Bogni A, Iwata R, Decise D, Crippa F, Bombardieri E (1999) High efficiency preparation of L-[S-methyl-11C]methionine by on-column [11C]methylation on C18 Sep-Pak. J Label Compd Radiopharm 42:715\u2013724. https:\/\/doi.org\/10.1002\/(SICI)1099-1344(199908)42:8%3c715::AID-JLCR224%3e3.0.CO;2-3","journal-title":"J Label Compd Radiopharm"},{"key":"1229_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.apradiso.2004.07.006","volume":"62","author":"M Mitterhauser","year":"2005","unstructured":"Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Eidherr H, Schmid A et al (2005) New aspects on the preparation of [11C]Methionine\u2014a simple and fast online approach without preparative HPLC. Appl Radiat Isot 62:441\u2013445. https:\/\/doi.org\/10.1016\/j.apradiso.2004.07.006","journal-title":"Appl Radiat Isot"},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S et al (2012) 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 30:1323\u20131341. https:\/\/doi.org\/10.1016\/j.mri.2012.05.001","journal-title":"Magn Reson Imaging"},{"key":"1229_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265\u2013273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ, Wu ZB (2018) Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59:50\u201361. https:\/\/doi.org\/10.1007\/s12020-017-1444-9","journal-title":"Endocrine"},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","volume":"18","author":"J Hu","year":"2015","unstructured":"Hu J, Zheng X, Zhang W, Yang H (2015) Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18:745\u2013751. https:\/\/doi.org\/10.1007\/s11102-014-0617-2","journal-title":"Pituitary"},{"key":"1229_CR52","doi-asserted-by":"publisher","first-page":"101356","DOI":"10.1016\/j.ghir.2020.101356","volume":"55","author":"HM Ozkaya","year":"2020","unstructured":"Ozkaya HM, Sahin S, Korkmaz OP, Durcan E, Sahin HR, Celik E et al (2020) Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res 55:101356. https:\/\/doi.org\/10.1016\/j.ghir.2020.101356","journal-title":"Growth Horm IGF Res"},{"key":"1229_CR53","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/eje-21-0977","volume":"186","author":"R Cozzi","year":"2022","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M et al (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol 186:P1-33. https:\/\/doi.org\/10.1530\/eje-21-0977","journal-title":"Eur J Endocrinol"},{"key":"1229_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ando.2021.11.008","volume":"83","author":"H Lasolle","year":"2022","unstructured":"Lasolle H, Teulade M, Lapras V, Vasiljevic A, Borson-Chazot F, Jouanneau E et al (2022) Postoperative remission of non-invasive lactotroph pituitary tumor: a single-center experience. Ann Endocrinol (Paris) 83:1\u20138. https:\/\/doi.org\/10.1016\/j.ando.2021.11.008","journal-title":"Ann Endocrinol (Paris)"},{"key":"1229_CR55","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","volume":"44","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, El-Koussy M, Widmer HR et al (2021) First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest 44:2621\u20132633. https:\/\/doi.org\/10.1007\/s40618-021-01569-6","journal-title":"J Endocrinol Invest"},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s42000-021-00309-y","volume":"20","author":"L Wei","year":"2021","unstructured":"Wei L, Wei X (2021) Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study. Hormones (Athens) 20:745\u2013752. https:\/\/doi.org\/10.1007\/s42000-021-00309-y","journal-title":"Hormones (Athens)"},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","volume":"185","author":"B Baussart","year":"2021","unstructured":"Baussart B, Villa C, Jouinot A, Raffin-Sanson ML, Foubert L, Cazabat L et al (2021) Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol 185:783\u2013791. https:\/\/doi.org\/10.1530\/EJE-21-0293","journal-title":"Eur J Endocrinol"},{"key":"1229_CR58","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab074","author":"MC Penn","year":"2021","unstructured":"Penn MC, Cardinal T, Zhang Y, Abt B, Bonney PA, Lorenzo P et al (2021) Cure and hormonal control after prolactinoma resection: case series and systematic review. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvab074","journal-title":"J Endocr Soc"},{"key":"1229_CR59","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.3346\/jkms.2021.36.e97","volume":"36","author":"K Park","year":"2021","unstructured":"Park K, Park KH, Park HR, Lee JM, Kim YH, Kim DY et al (2021) Long-term outcome of microscopic transsphenoidal surgery for prolactinomas as an alternative to dopamine agonists. J Korean Med Sci 36:e97. https:\/\/doi.org\/10.3346\/jkms.2021.36.e97","journal-title":"J Korean Med Sci"},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/a-1247-4908","volume":"129","author":"S Giese","year":"2021","unstructured":"Giese S, Nasi-Kordhishti I, Honegger J (2021) Outcomes of transsphenoidal microsurgery for prolactinomas-a contemporary series of 162 cases. Exp Clin Endocrinol Diabetes 129:163\u2013171. https:\/\/doi.org\/10.1055\/a-1247-4908","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fendo.2020.00439","volume":"11","author":"G Zielinski","year":"2020","unstructured":"Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P (2020) Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front Endocrinol (Lausanne) 11:439. https:\/\/doi.org\/10.3389\/fendo.2020.00439","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1229_CR62","doi-asserted-by":"publisher","first-page":"e13198","DOI":"10.1097\/MD.0000000000013198","volume":"97","author":"YL Han","year":"2018","unstructured":"Han YL, Chen DM, Zhang C, Pan M, Yang XP, Wu YG (2018) Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Med (United States) 97:e13198. https:\/\/doi.org\/10.1097\/MD.0000000000013198","journal-title":"Med (United States)"},{"key":"1229_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00636","author":"Q Ma","year":"2018","unstructured":"Ma Q, Su J, Li Y, Wang J, Long W, Luo M et al (2018) The chance of permanent cure for micro- And macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2018.00636","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","volume":"24","author":"KJ Yagnik","year":"2021","unstructured":"Yagnik KJ, Erickson D, Bancos I, Atkinson JLD, Choby G, Peris-Celda M et al (2021) Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24:978\u2013988. https:\/\/doi.org\/10.1007\/s11102-021-01188-7","journal-title":"Pituitary"},{"key":"1229_CR65","doi-asserted-by":"publisher","first-page":"101278","DOI":"10.1016\/j.beem.2019.05.002","volume":"33","author":"WA Bashari","year":"2019","unstructured":"Bashari WA, Senanayake R, Fern\u00e1ndez-Pombo A, Gillett D, Koulouri O, Powlson AS et al (2019) Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 33:101278. https:\/\/doi.org\/10.1016\/j.beem.2019.05.002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1229_CR66","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1530\/EJE-15-1272","volume":"175","author":"V Vasilev","year":"2016","unstructured":"Vasilev V, Rostomyan L, Daly AF, Potorac L, Zacharieva S, Bonneville JF et al (2016) Pituitary \u201cincidentaloma\u201d: neuroradiological assessment and differential diagnosis. Eur J Endocrinol 175:R171\u2013R184. https:\/\/doi.org\/10.1530\/EJE-15-1272","journal-title":"Eur J Endocrinol"},{"key":"1229_CR67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11102-018-0928-9","volume":"22","author":"J-F Bonneville","year":"2019","unstructured":"Bonneville J-F (2019) A plea for the T2W MR sequence for pituitary imaging. Pituitary 22:195\u2013197. https:\/\/doi.org\/10.1007\/s11102-018-0928-9","journal-title":"Pituitary"},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","volume":"23","author":"EV Varlamov","year":"2020","unstructured":"Varlamov EV, Hinojosa-Amaya JM, Fleseriu M (2020) Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 23:16\u201326. https:\/\/doi.org\/10.1007\/s11102-019-01001-6","journal-title":"Pituitary"},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 20:489\u2013498. https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01229-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T10:21:36Z","timestamp":1659435696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01229-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"3 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Authors have no competing interests, or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in accordance with Good Clinical Practice and the principles in the Declaration of Helsinki. The study received institutional approval from Cambridge University Hospitals NHS Foundation Trust (CUH QSIS 2020: 3039).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants were appropriately consented before any study procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final manuscript for submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}